Over the past six months, Moderna’s shares (currently trading at $25.79) have posted a disappointing 19.2% loss, well below ...

Moderna’s second quarter results were met with a negative market reaction, as investors focused on both a sharp decline in ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

Six months into Donald Trump’s second term, his administration is at war with the federal judiciary, evading court orders ...

NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced last week that his department would slash about $500 ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Scientists used IBM's R2 Heron quantum processor to predict the secondary protein structure of a 60-nucleotide-long mRNA ...

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...

Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

The U.S. health secretary ordered an end to new mRNA development efforts just after UTMB published new research showing its ...